Bay Labs, a medical technology company developing an artificial intelligence in cardiovascular imaging, has announced that its chief medical officer Randolph P Martin (Emory University School of Medicine, Atlanta, USA) is to speak at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA).
A press release reports that Martin’s two presentations will focus on how advances in artificial intelligence, machine learning, and deep learning can impact the role that cardiovascular imaging and echocardiography play in the diagnosis and management of heart diseases, especially those affecting the heart valves. Additionally, TCT attendees will have the opportunity to learn more about artificial intelligence and deep learning’s role in echocardiography and valvular heart diseases at the following presentations being made by:
- Using artificial intelligence (Machine Learning) to direct acquisition and interpretation of echocardiograms—improving access and quality of valve disease diagnosis; 30 October, 4.04pm; Mile High Ballroom 2B-3B.
- Advances in structural heart disease imaging (Workflow advances, automated quantification, and machine learning); 1 November 1.15pm; Room 605.
Today, physicians seek consistent, high-quality imaging studies with quantitative assessments from imaging labs to the point of care. Such studies aid in the timely and appropriate diagnosis and treatment of heart disease around the world. Deep learning, a type of artificial intelligence algorithm, has great promise to aid in the acquisition and interpretation of echocardiographic exams and may improve the treatment of heart diseases.
